201 related articles for article (PubMed ID: 31266376)
1. Preparation and
Zhou T; Tang X; Zhang W; Feng J; Wu W
Drug Deliv; 2019 Dec; 26(1):673-679. PubMed ID: 31266376
[TBL] [Abstract][Full Text] [Related]
2. Preparation, Characterization, and in vivo Evaluation of NK4-Conjugated Hydroxycamptothecin-Loaded Liposomes.
Zhou T; Zhang W; Cheng D; Tang X; Feng J; Wu W
Int J Nanomedicine; 2020; 15():2277-2286. PubMed ID: 32280220
[TBL] [Abstract][Full Text] [Related]
3. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
[TBL] [Abstract][Full Text] [Related]
4. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles.
Yang L; Cui F; Cun D; Tao A; Shi K; Lin W
Int J Pharm; 2007 Aug; 340(1-2):163-72. PubMed ID: 17482779
[TBL] [Abstract][Full Text] [Related]
5. Hydroxycamptothecin liposomes based on thermal and magnetic dual-responsive system: preparation, in vitro and in vivo antitumor activity, microdialysis-based tumor pharmacokinetics.
Zhu HM; Gu JH; Xie Y; Xie B; Ling JJ
J Drug Target; 2018 Apr; 26(4):345-356. PubMed ID: 28920483
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of bioavailability of two kinds of solid dispersion from 10-hydroxycamptothecin in SD rats in vivo].
Wu XC; Hao HJ; Liu YX; Song XY; Zhang YZ; Zhang HQ
Zhongguo Zhong Yao Za Zhi; 2016 Mar; 41(6):1130-1134. PubMed ID: 28875682
[TBL] [Abstract][Full Text] [Related]
7. [Preparation of PEG-modified nanostructured lipid carriers loaded with hydroxycamptothecin and tissue distribution in mice].
Zhang XX; Gan Y; Yang XG; Zhu CL; Gan L; Nie SF; Pan WS
Yao Xue Xue Bao; 2008 Jan; 43(1):91-6. PubMed ID: 18357740
[TBL] [Abstract][Full Text] [Related]
8. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
[TBL] [Abstract][Full Text] [Related]
9. [In vivo imaging in tumor-bearing animals and pharmacokinetics of PEGylated liposomes modified with RGD cyclopeptide].
Tu LX; Xu YH; Tang CY; Deng LH; Wu CB
Yao Xue Xue Bao; 2012 May; 47(5):646-51. PubMed ID: 22812011
[TBL] [Abstract][Full Text] [Related]
10. Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect.
Wang A; Li S
BMC Biotechnol; 2008 May; 8():46. PubMed ID: 18454874
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, biodistribution and antitumor efficacy of hydroxycamptothecin nanosuspensions.
Han M; Liu X; Guo Y; Wang Y; Wang X
Int J Pharm; 2013 Oct; 455(1-2):85-92. PubMed ID: 23928147
[TBL] [Abstract][Full Text] [Related]
12. A polymeric micelle with an endosomal pH-sensitivity for intracellular delivery and enhanced antitumor efficacy of hydroxycamptothecin.
Pu X; Zhao L; Li J; Song R; Wang Y; Yu K; Hou X; Qiao P; Zong L; Chang S
Acta Biomater; 2019 Apr; 88():357-369. PubMed ID: 30822554
[TBL] [Abstract][Full Text] [Related]
13. Preparation of 10-hydroxycamptothecin-loaded glycyrrhizic acid-conjugated bovine serum albumin nanoparticles for hepatocellular carcinoma-targeted drug delivery.
Zu Y; Meng L; Zhao X; Ge Y; Yu X; Zhang Y; Deng Y
Int J Nanomedicine; 2013; 8():1207-22. PubMed ID: 23569373
[TBL] [Abstract][Full Text] [Related]
14. Lipid nanoparticles loaded with 10-hydroxycamptothecin-phospholipid complex developed for the treatment of hepatoma in clinical application.
Wei W; Shi SJ; Liu J; Sun X; Ren K; Zhao D; Zhang XN; Zhang ZR; Gong T
J Drug Target; 2010 Aug; 18(7):557-66. PubMed ID: 20131981
[TBL] [Abstract][Full Text] [Related]
15. [Distribution of hydroxycamptothecin after aerosol inhalation in rabbits].
Chen J; Fang Y; Zhang HX; Huang LL; Qian XP; Liu BR
Yao Xue Xue Bao; 2004 Sep; 39(9):747-51. PubMed ID: 15606028
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tissue distribution study of 10-methoxycamptothecin in rats following intragastric administration.
Zheng J; Ji Y; Shao C; Jing L; Wang Y
J Pharm Biomed Anal; 2018 Feb; 149():564-571. PubMed ID: 29197298
[TBL] [Abstract][Full Text] [Related]
17. 10-Hydroxycamptothecin (HCPT) nanosuspensions stabilized by mPEG
Yang L; Hong J; Di J; Guo Y; Han M; Liu M; Wang X
Int J Nanomedicine; 2017; 12():3681-3695. PubMed ID: 28553107
[TBL] [Abstract][Full Text] [Related]
18. Sustained release of hydroxycamptothecin after subcutaneous administration using a novel phospholipid complex-DepoFoam technology.
Zhao Y; Liu J; Sun X; Zhang ZR; Gong T
Drug Dev Ind Pharm; 2010 Jul; 36(7):823-31. PubMed ID: 20515403
[TBL] [Abstract][Full Text] [Related]
19. In-vivo pharmacokinetics, tissue distribution and anti-tumour effect of hydroxycamptothecin delivered in oil-in-water submicron emulsions.
Zhao YX; Liu DX; Liang WQ; Ye ZW
J Pharm Pharmacol; 2012 Jun; 64(6):783-91. PubMed ID: 22571256
[TBL] [Abstract][Full Text] [Related]
20. Enhanced tumor targeting and antitumor efficacy via hydroxycamptothecin-encapsulated folate-modified N-succinyl-N'-octyl chitosan micelles.
Zhu H; Cao J; Cui S; Qian Z; Gu Y
J Pharm Sci; 2013 Apr; 102(4):1318-32. PubMed ID: 23400693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
